Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-35627384

RESUMO

Mixed land use provides an important means of promoting the intensive and efficient use of land resources and stimulating endogenous development power in rural areas. This paper selected Pingba Village in Chongqing as the research area; the land use status data and the social and economic data on rural settlements in the study area for 2021 were obtained through field visits and interviews. Moreover, the land use types in the rural settlements were subdivided according to the principle of dominant function. Based on these subdivisions, a land mixed-use measurement system for rural settlements was constructed to analyze their levels of mixed land use. Furthermore, the influences of natural environmental, social, economic and other factors on mixed land use were comprehensively explored. The results showed that, (1) the mixed land use of rural settlements in the study area was at a medium level and showed significant spatial variability, and rural settlements in the high, medium and low mixed land use index zones accounted for 12.5%, 35% and 52.5% of the total, respectively. (2) The differences in the natural environment determined the level of mixed land use and the basic pattern of its spatial differentiation. Social and economic factors, such as resident population and average household income, were key impact factors. Rural tourism resources, homestead agglomeration policies and other factors had important impacts on the level of mixed land use. In conclusion, the research suggests that mixed land use is an important way to boost rural revitalization. In the future, village planning could introduce the concept of mixed land use to improve the efficiency of land use, optimize the land use structure according to local conditions and promote the integrated development of rural primary, secondary and tertiary industries. In addition, it is necessary to scientifically and rationally guide rural settlements to agglomerate appropriately to improve the utilization efficiency of land resources and public service resources.


Assuntos
Indústrias , População Rural , China , Meio Ambiente , Humanos , Turismo
2.
Future Oncol ; 18(22): 2393-2402, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35510486

RESUMO

Imetelstat, a first-in-class telomerase inhibitor, demonstrated meaningful clinical benefit including a robust symptom response rate and potential overall survival benefit in IMbark, a phase II study in intermediate-2 or high-risk myelofibrosis (MF) patients who have relapsed after or are refractory to JAK inhibitors. We describe the rationale and design for the phase III trial, IMpactMF (NCT04576156), an open-label evaluation of imetelstat versus best available therapy, excluding JAK inhibitors, in MF patients refractory to JAK inhibitor. Imetelstat 9.4 mg/kg is administered as an intravenous infusion every 21 days. Primary objective is to assess overall survival. Secondary objectives include symptom and spleen responses, progression-free survival, clinical response assessment, bone marrow fibrosis reduction, safety and pharmacokinetics. Biomarker, cytogenetics and mutation analyses will be performed.


Imetelstat is a new type of treatment being studied in patients with myelofibrosis (MF). Encouraging clinical benefits were seen in a phase II clinical trial of imetelstat in higher risk MF. This article discusses the ongoing phase III trial, called IMpactMF. IMpactMF is comparing imetelstat to best available therapy (BAT) in MF patients not responding to a specific type of treatment, a JAK inhibitor. Imetelstat is an intravenous infusion, given every 21 days. This study will determine if patients who receive imetelstat live longer than patients who are given BAT. It will also collect information on additional outcomes, including safety. Trial Registration Number: NCT04576156 (ClinicalTrials.gov).


Assuntos
Inibidores de Janus Quinases , Mielofibrose Primária , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Humanos , Nitrilas/uso terapêutico , Oligonucleotídeos , Mielofibrose Primária/diagnóstico , Mielofibrose Primária/tratamento farmacológico , Pirazóis/uso terapêutico , Pirimidinas/efeitos adversos
3.
Eur Urol ; 82(3): 283-292, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-35210132

RESUMO

BACKGROUND: Lenvatinib (18 mg) plus everolimus (5 mg) is approved for patients with advanced renal cell carcinoma (RCC) after one or more prior antiangiogenic therapies. OBJECTIVE: To assess whether a lower starting dose of lenvatinib has comparable efficacy with improved tolerability for patients with advanced RCC treated with lenvatinib plus everolimus. DESIGN, SETTING, AND PARTICIPANTS: A randomized, open-label, phase 2 global trial was conducted in patients with advanced clear cell RCC and disease progression after one prior vascular endothelial growth factor-targeted therapy (prior anti-programmed death-1/programmed death ligand-1 therapy permitted). INTERVENTION: Patients were randomly assigned 1:1 to the 14- or 18-mg lenvatinib starting dose, both in combination with everolimus 5 mg/d. Patients in the 14-mg arm were to be uptitrated to lenvatinib 18 mg at cycle 2, day 1, barring intolerable grade 2 or any grade ≥3 treatment-emergent adverse events (TEAEs) requiring dose reduction occurring in the first 28-d cycle. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary efficacy endpoint was investigator-assessed objective response rate (ORR) as of week 24 (ORRwk24); the noninferiority threshold of the 14- versus 18-mg arm was p ≤ 0.045. The primary safety endpoint was the proportion of patients with intolerable grade 2 or any grade ≥3 TEAEs within 24 wk of randomization. RESULTS AND LIMITATIONS: The ORRwk24 for the 14-mg arm (32% [95% confidence interval {CI} 25-39]) was not noninferior to the ORRwk24 in the 18-mg arm (35% [95% CI 27-42]; odds ratio: 0.88; 90% CI 0.59-1.32; p = 0.3). The proportion of intolerable grade 2 or any grade ≥3 TEAEs was similar between the two arms (14 mg, 83% vs 18 mg, 80%; p = 0.5). The secondary endpoints of overall ORR, progression-free survival, and overall survival numerically favored the 18-mg arm. A limitation of this study was that the study design did not allow for a full comparison of progression-free survival between treatment arms. CONCLUSIONS: The study findings support the approved dosing regimen of lenvatinib 18 mg plus everolimus 5 mg daily for patients with advanced RCC. PATIENT SUMMARY: In this report, we examined two doses of lenvatinib (the approved 18-mg dose and a lower dose of 14 mg) in people with advanced renal cell carcinoma to determine whether the lower dose (which was increased to the approved 18-mg dose after the first treatment cycle) could improve safety without affecting efficacy. The results showed that the efficacy of the lower lenvatinib dose (14 mg) was not the same as that of the approved (18 mg) dose, although safety results were similar, so the approved lenvatinib 18-mg dose should still be used.


Assuntos
Carcinoma de Células Renais , Neoplasias Renais , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma de Células Renais/patologia , Everolimo/efeitos adversos , Humanos , Neoplasias Renais/patologia , Compostos de Fenilureia , Quinolinas , Fator A de Crescimento do Endotélio Vascular
4.
J Clin Pharmacol ; 55(12): 1406-14, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26096139

RESUMO

Food effect on abiraterone pharmacokinetics and safety on abiraterone acetate coadministration with low-fat or high-fat meals was examined in healthy subjects and metastatic castration-resistant prostate cancer (mCRPC) patients. Healthy subjects (n = 36) were randomized to abiraterone acetate (single dose, 1000 mg) + low-fat meal, + high-fat meal, and fasted state. mCRPC patients received repeated doses (abiraterone acetate 1000 mg + 5 mg prednisone twice daily; days 1-7) in a modified fasting state followed by abiraterone acetate plus prednisone within 0.5 hours post-low-fat (n = 6) or high-fat meal (n = 18; days 8-14). In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively). In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively). Adverse events (all grade ≤ 3) were similar, with high-fat/low-fat meals or fasted/modified fasting state. Short-term dosing with food did not alter abiraterone acetate safety.


Assuntos
Acetato de Abiraterona/farmacocinética , Gorduras na Dieta/farmacologia , Interações Alimento-Droga , Neoplasias de Próstata Resistentes à Castração/metabolismo , Acetato de Abiraterona/efeitos adversos , Acetato de Abiraterona/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Inibidores das Enzimas do Citocromo P-450/efeitos adversos , Inibidores das Enzimas do Citocromo P-450/sangue , Inibidores das Enzimas do Citocromo P-450/farmacocinética , Quimioterapia Combinada , Jejum/metabolismo , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Prednisona/efeitos adversos , Neoplasias de Próstata Resistentes à Castração/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA